Return to content in this issue

 

COVID-19 Vaccine Tolerability in a Patient With a Delayed Allergic Reaction to Polyethylene Glycol: A Case Report

Loli-Ausejo D1,2,3, Gómez-Armayones S2,4,5, Sáez-Peñataro J2,5,6, González-Matamala MF1,3, Mascaró B1,3, Muñoz-Cano R1,2,3,5,7, Bartra J1,2,3,5,7

1Department of Allergy, Hospital Clínic de Barcelona, Barcelona, Spain
2University of Barcelona, Barcelona, Spain
3Clinical and Experimental Respiratory Immunoallergy (IRCE), August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
4Department of Dermatology, Hospital Clínic de Barcelona, Barcelona, Spain
5Technical Committee for Pharmacovigilance, Hospital Clínic de Barcelona, Barcelona, Spain
6Department of Clinical Pharmacology, Medicines Division, Hospital Clínic de Barcelona, Barcelona, Spain
7Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS), Red de Enfermedades Inflamatorias, Instituto de Salud Carlos III, Madrid, Spain

J Investig Allergol Clin Immunol 2023; Vol 33(3) : 232-233
doi: 10.18176/jiaci.0843

Key words: COVID-19, COVID-19 vaccine, Polyethylene glycols, Vaccine excipients, Hypersensitivity